Skip to main content
OpenTrials
Completed

NCT Number: NCT02896920

Canadian Humira Post Marketing Observational Epidemiological Study : Assessing Humira Real-life Effectiveness and Impact on HS Burden of Illness

This study assesses Humira's® real-life effectiveness in the management of dermatological manifestations of moderate to severe Hidradenitis Suppurativa (HS).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–99 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Institute for Skin Advancement /ID# 152448, Calgary, Alberta, Canada

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Has a clinical diagnosis of moderate to severe HS according to the treating physician judgment
  • Need a change in ongoing therapy for any reason, but not limited to inadequate response, intolerance, sub-optimal compliance, or patient preference. Patient will be approached to participate in the study after a decision to change patient's therapy for Humira® is made by the treating physician.
  • Has provided written informed consent (Patient Authorization) for participation in the study

Exclusion criteria

  • Is participating in a clinical interventional study
  • Was treated with Humira®, or any other biologic agents for HS prior to baseline visit
  • Has any other active skin disease or condition that, in the opinion of the treating physician, prohibits the patient from participating in the study or obscures the assessment of the treatment of HS

Treatment and study plan

Primary outcomes

  1. Proportion of participants achieving clinical response using the Hidradenitis Suppurativa Clinical Response measure (HiSCR) at week 24

    Time frame: At Week 24

    The HiSCR measure is defined as at least a 50% reduction in the Abscess and inflammatory nodule (AN) count with no increase in abscess count and no increase in draining fistula count relative to baseline.

Secondary outcomes

  1. Proportion of participants who experience flare

    Time frame: Up to Week 52

    It is defined as at least 25% increase in AN counts with a minimum increase of 2 relative to baseline

  2. Change from Baseline in Hospital Anxiety and Depression Scale (HADS)

    Time frame: From Week 0 (baseline) to Week 52

    The HADS questionnaire includes 14 questions that evaluate the level of anxiety and depression an HS patient may experience associated with HS. A lower score indicates less severity.

  3. Change from Baseline in International Index of Erectile Function (IIEF)

    Time frame: From Week 0 (baseline) to Week 52

    The IIEF contains 15 questions that were assigned in 5 domains of male sexuality: erectile function, orgasmic function, sexual desire, intercourse satisfaction, and overall satisfaction.

  4. Change from Baseline in Health Care Resource Utilization (HCRU) associated with HS

    Time frame: From Week 0 (baseline) to Week 52

    This will be assessed using a descriptive questionnaire that aimed at measuring the patient's health care resource utilization and economic impact of HS.

  5. Change from Baseline in Patient Global Assessment of HS (HS-PtGA)

    Time frame: From Week 0 (baseline) to Week 52

    The HSPtGA consists in one question that evaluates how one patient ranked the severity of HS at the time of the routine visit.

  6. Proportion of participants achieving clinical response using the Hidradenitis Suppurativa Clinical Response measure (HiSCR) at week 52

    Time frame: At Week 52

    The HiSCR measure is defined as at least a 50% reduction in the Abscess and inflammatory nodule (AN) count with no increase in abscess count and no increase in draining fistula count relative to baseline.

  7. Change from Baseline in Health Utility Index Mark 3 (HUI3)

    Time frame: From Week 0 (baseline) to Week 52

    This is a comprehensive system for measuring health status and health-related quality of life and for producing utility scores.

  8. Change from Baseline in Female Sexual Function Index (FSFI)

    Time frame: From Week 0 (baseline) to Week 52

    The FSFI questionnaire contains 19 questions that describe the female sexual function in 6 domains. The domains are: desire, arousal, lubrication, orgasm, satisfaction, and pain, which can both be evaluated individually and in their entirety.

  9. Proportion of participants who experience worsening of HS by >= 1 Hurley Stage in >= 1 affected anatomic region

    Time frame: Up to Week 52

    This will be done by evaluating the Hurley Stage using the following description:

    Stage I: Abscess formation, single or multiple, without sinus tracts and cicatrization (scarring).

    Stage II: One or more widely separated recurrent abscesses with tract formation and cicatrization (scars).

    Stage III: Multiple interconnected tracts and abscesses across the entire area, with diffuse or near diffuse involvement.

  10. Change from Baseline in Hidradenitis Suppurativa Symptom Assessment (HSSA)

    Time frame: From Week 0 (baseline) to Week 52

    The HSSA questionnaire includes 9 questions that evaluate the symptoms an HS participant may experience associated with HS.

  11. Change from Baseline in Hidradenitis Suppurativa Impact Assessment (HSIA)

    Time frame: From Week 0 (baseline) to Week 52

    The HSIA questionnaire includes 18 questions that evaluate the impacts an HS participant may experience associated with HS.

  12. Change from Baseline in Work Productivity and Activity Impairment Questionnaire: Specific Health Problem V2.0 (WPAI: SHP)

    Time frame: From Week 0 (baseline) to Week 52

    The WPAI: SHP evaluates four areas: percent work time missed due to HS, percent impairment while working due to HS, percent overall work impairment due to HS, and percent activity impairment due to HS.

  13. Number of days where participants experience HS flare-up

    Time frame: Up to Week 52

    It is calculated from the day when flare is observed to the day prior to the observation that flare is no longer present. Of note, there could be multiple periods that flares are observed, in which case, the total days from the multiple periods will be used.

Sponsors and collaborators

Lead sponsor

AbbVie

Industry

Registry information

Official study title

Canadian Humira Post Marketing Observational Epidemiological Study : Assessing Humira Real-life Effectiveness and Impact on Hidradenitis Suppurativa (HS) Burden of Illness and Health Care Resources Utilization

Acronym: SOLACE

Important dates

Study start
2016
Primary completion
2019
Study completion
2019
First posted
Sep 12, 2016
Registry last updated
May 1, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.